Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. neofibrin

NEOFIBRIN

Advanced material for the regeneration of oral mucosa injuries

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 NEOFIBRIN project word cloud

Explore the words cloud of the NEOFIBRIN project. It provides you a very rough idea of what is the project "NEOFIBRIN" about.

yield    innovative    alternative    successful    techniques    gives    clinical    biomaterial    mechanical    facility    fibrin    treat    accelerating    grafts    histocell    damage    hr018    tissues    industrialization    company    seek    materials    efficiency    suturing    surgical    phases    functional    tridimensional    tissue    manufacturing    sme    extracellular    treatment    facilitates    cell    marketed    completion    plan    polysaccharide    regenerative    mucosal    injuries    provides    business    matrix    proteins    consistency    market    combining    ce    artificial    adapt    supportive    specialized    scaffold    significantly    seaweed    allogenic    localized    oral    regeneration    larger    instrument    mark    structural    agarose    progressive    restoring    epithelium    material    wound    capacity    scaffolds    feasibility    rights    masticatory    sem    maturation    mucosa    medical    dentistry    invasion    autologous    obtain    temporary    medicine    licensing    proliferation    migration    engineering    neofibrin    maintaining    accomplishment    healing    natural    exclusive    generation    human   

Project "NEOFIBRIN" data sheet

The following table provides information about the project.

Coordinator		 HISTOCELL SL 

Organization address
address: PARQUE TECNOLOGICO DE BIZKAIA EDIFICIO 801 PISO 2
city: DERIO BIZKAIA
postcode: 48160
website: www.histocell.com

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Spain [ES]
 Project website http://www.histocell.com/index.php/en/r-d/current-projects/138-neofibrin
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.2.1.5. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced manufacturing and processing)
2. H2020-EU.2.1.3. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced materials)
3. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
4. H2020-EU.2.1.2. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2017
 Duration (year-month-day) from 2017-02-01   to  2017-07-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    HISTOCELL SL ES (DERIO BIZKAIA) coordinator 50˙000.00

Map

 Project objective

The main objective of NEOFIBRIN is to undertake a technical, industrialization and market feasibility study on an innovative regenerative medicine treatment for masticatory oral mucosa injuries based on a new advanced material, HR018-Neofibrin. The use of this material to develop a tridimensional natural scaffold for restoring masticatory oral mucosa functional activity is expected to significantly increase treatment efficiency over currently marketed products and to provide an alternative to allogenic and autologous grafts to treat localized mucosal damage. The application of Tissue Engineering techniques in clinical dentistry has several well-known problems, key among them the generation of a supportive biomaterial with regenerative capacity without the loss of consistency. Our novel biomaterial HR018-Neofibrin was developed combining natural materials and an exclusive design to promote the progressive formation and maturation of new epithelium while maintaining structural properties. Fibrin, one of the proteins involved in wound healing, provides a temporary extracellular matrix that facilitates cell migration, invasion and proliferation. Agarose, a polysaccharide from seaweed, gives the mechanical properties that enable surgical suturing and open healing. Histocell, a SME specialized in human regenerative medicine, has obtained licensing rights to the production of fibrin-agarose based artificial tissues and scaffolds for regeneration of tissues and oral mucosa. Successful completion of Phase 1 of NEOFIBRIN will yield a robust business plan for a much larger project that will seek funding under Phase 2 of the SEM Instrument, when the company will adapt a new facility for advanced manufacturing of innovative medical devices for the production of the new biomaterial HR018-Neofibrin and undertake clinical studies to obtain CE Mark for the product. Successful accomplishment of Phases 1 and 2 will be essential for accelerating the growth of the SME Histocell.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NEOFIBRIN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NEOFIBRIN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.5.;H2020-EU.2.1.3.;H2020-EU.2.3.1.;H2020-EU.2.1.2.)

SHN (2017)

Universal Smart Hypodermic Needle for preventing reuse and accidental pricks

Read More  

SUPPLEPRINT (2018)

Super Productive Line Printing Inkjet

Read More  

Gri3D (2018)

The industrialization and market entry of a novel bioengineered hydrogel grid to standardize stem cell cultures for precision medicine.

Read More